Neuroimaging biomarkers for AD

Structural Functional And Molecular Neuroimaging Biomarkers For Alzheimer’s Disease

Magnetic resonance spectroscopy (MRS) has long showed promise for detection of regional chemical changes associated with neurodegeneration, infl ammation, or gliosis, and so it has been a technique of interest for detecting such changes in AD. It provides information about relative concentrations of key chemicals, such as N acetylaspartate, creatinine, and myoinositol, and there is strong evidence that the regional concentration of these chemicals varies with the neurodegeneration seen in AD. (2013).

[button]Download[/button]

More Resources

07/29/2026

Read Your Segmentations in the Same Space You Read the Study: Native Space Outputs in NeuroQuant v5.3.0

Review lesion segmentations directly on your original MRI images with NeuroQuant® v5.3.0.

07/23/2026

What AAIC 2026 Told Us About the Future of Dementia Imaging — And Where NeuroQuant Fits

Quantitative MRI brain volumetry with NeuroQuant.

07/09/2026

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration

Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai’s health system network

07/08/2026

The Hidden Tax on Every Head CT You Read

Why automated, consistent alignment, and the reformats it makes possible, may be the most overlooked upgrade in neuroimaging.

06/23/2026

Helping Our Clients Share Their Success Stories

Learn how Cortechs helps clients share clinical achievements, workflow improvements, and innovation through case studies, testimonials, webinars, and more.

06/15/2026

Alzheimer’s Awareness Month: Bringing Clarity to the Alzheimer’s Care Continuum Through Quantitative Imaging

Explore how quantitative imaging is helping clinicians assess, diagnose, and monitor Alzheimer’s disease and related dementias with greater clarity.
Scroll to Top